A Fortune article published on June 16, 2025, titled I had one simple surgery to lower my risk of the deadliest cancer for women. Here’s why you probably don’t know about it—but should, highlights an effective but underused way to reduce the risk of ovarian cancer: opportunistic salpingectomy, the removal of the fallopian tubes during another … Continued
New collaboration enhances support for gynecologic cancer patients through integrated digital and personalized care New York, NY — [June 11, 2025] — Ovarian Cancer Research Alliance (OCRA), the largest global organization dedicated to advancing ovarian and all gynecologic cancer research and supporting patients and their families, is proud to announce a strategic partnership with Iris by … Continued
Global Collaborative Research Push Resonates Across Airwaves The launch of the Global Ovarian Cancer Research Consortium has garnered significant media attention, with coverage appearing on NBC News Radio, FOX 5 Washington D.C., KUNS-TV Seattle, WRC-TV Washington D.C. (NBC), WJFF-FM New York (NPR affiliate), and FemTech Insider, among others. The Consortium’s inaugural initiative is a new AI Accelerator Grant — a … Continued
FY26 Budget Watch, Advocacy Results, and State-Level Progress As Congress ramps up work on the FY26 federal budget, advocates are focused on maintaining vital cancer programs and advancing state policies that support gynecologic cancer patients. Here’s what’s happened over the last month—and what’s next. Budget Update: CDC Cancer Programs at Risk The administration’s proposed FY26 … Continued
Uterine (or endometrial) cancer is the most common type of gynecologic cancer, with more than 886,000 women living with the disease in the U.S., according to National Cancer Institute’s SEER Cancer Statistics. As Ovarian Cancer Research Alliance funds research that aims to cure ovarian and related gynecologic cancers, we are here for those impacted by … Continued
In a wide-ranging interview on the podcast Out of Patients with Matthew Zachary, OCRA’s President & CEO Audra Moran delves into the evolution of the organization, the unique programs offered by OCRA such as our peer mentorship program Woman to Woman, and thoughts on how AI may revolutionize ovarian cancer research. Listen to the podcast … Continued
The Food and Drug Administration has granted accelerated approval to Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets), made by Verastem Oncology, making it the first FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC) who have a KRAS mutation. The approval is based on the results of the Phase 2 RAMP 201 clinical … Continued
Liliana is a mother, a wife, a dedicated volunteer and a former physician. While her cancer diagnosis forced her into early retirement, her mission to help others never wavered. Today, OCRA programs made possible by donor generosity, allow her to give back and make someone else’s journey a little easier, all while healing a part … Continued
News of the newly launched Global Ovarian Cancer Research Consortium — and its inaugural AI Accelerator Grant — is spreading quickly, with media outlets across the country taking notice. The AI Accelerator Grant will award $1 million in funding, along with $1 million in compute support from Microsoft’s AI for Good Lab, to international research … Continued
Four leading ovarian cancer research charities from four countries are funding a new AI Accelerator Grant in partnership with Microsoft’s AI for Good Lab to supercharge the next cancer research breakthrough. [May 8, 2025] – Today marks World Ovarian Cancer Day and the launch of the Global Ovarian Cancer Research Consortium — a first-of-its-kind alliance uniting … Continued
In the newest installment of our continuing introduction of our 2025 grantees, Ovarian Cancer Research Alliance (OCRA) is proud to highlight the three recipients of our 2025 Health Equity Research Grants, part of the $6 million in new research OCRA is funding this year. These grants support research focused on identifying and addressing disparities in ovarian … Continued
On behalf of the millions of Americans living with cancer and at risk for being diagnosed, as well as health care providers, researchers, advocates, and their communities, we express our profound disappointment and grave concern regarding the proposed elimination of the Centers for Disease Control and Prevention’s Division of Cancer Prevention and Control (DCPC) in … Continued
Get email updates about research news, action alerts, and ways to join the fight.
